A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients

Objective: In platinum-resistant ovarian cancer weekly paclitaxel has shown an equal efficiency and better toxicity profile compared to three-weekly paclitaxel in platinum-resistant ovarian cancer. We wanted to study response rate, response duration and toxicity in platinum-resistant tumors with emphasis on tumors also resistant to three-weekly paclitaxel.

Material and methods: Fifty-seven patients with platinum-resistant disease, treated with weekly paclitaxel 80 mg/m2, 1-hour infusion, were evaluable for response and toxicity (Group A). Of these, 39 patients (Group B) had tumors resistant to paclitaxel as well.

Results: Overall response rate was 56% (12% CR, 44% PR, 19% SD, 25% PD) and 49% in group B: 5% CR, 44% PR, 23% SD, 28% PD. Median progression-free survival was 5.0 months and 4.0 months in group A and B, respectively. Median survival was 13.7 months in both groups. Toxicity was mild. Only two patients had grade 2 neutropenia and no neutropenic fever was recorded. No worsening in pre-existing neurotoxicity or hypersensitivity reactions was observed.

Conclusion: Weekly administration of paclitaxel is associated with promising response rates in patients with platinum- and paclitaxel-resistant ovarian cancer. The treatment is well tolerated with non-cumulative hematologic and non-hematologic toxicity.

Weekly paclitaxel; Platinum- and Paclitaxel-resistant ovarian cancer

[1] Pisani P., Parkin D. M., Fearlay J.: "Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden". Int. J. Cancer, 1993, 55, 891.

[2] Petterson F.: Annual Report on Results of Treatment in Gynecological Cancer. Stockholm, Sweden, International Federation of Gynecology and Obstetrics 1994.

[3] Balvert L. H., Coebergh J. W., Hop W. C. et al.: "Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study". Gynecol. Oncol., 1991, 42, 3.

[4] Bj(llrge T., Engeland A., Hansen S., Trope C.: "Prognosis of patients with ovarian cancer and borderline tumour diagnoses in Norway between 1954 and 1993". lnt. J. Cancer, 1998, 75, 663.

[5] Piver M.: "Ovarian carcinoma: A decade of progress". Cancer, 1994, 54 (Suppl 11), 2706.

[6] Wiltshaw E., Subramarian S., Alexopoulos C., Barker G. H.: "Cancer of the ovary: A summary of experience with cis-dichlorodiamninplatinum(11) at the Royal Marsden Hospital". Cancer Treat. Rep., 1979, 63, 1545.

[7] Trope C., Kristensen G.: "Current status of chemotherapy in gynecologic cancer". Semin. Oncol., 1997, 24, 1521.

[8] Ovarian Cancer Meta-analysis Project: "Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis". J. Clin. Oncol., 1991, 9, 1668.

[9] McGuire W. P., Hoskins W. J., Brady M. F. et al.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer". N. Engl. J. Med., 1996, 334, 1.

[10] Vergote I., Himmelmann A., Frankendal B., Scheistroen M., V lachos K., Trope C.: "Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer". Gynecol. Oncol., 1992, [11] Markman M., Hakes T., Reichman B., Lewis J. L., Rubin S., Jones W. et al.: "Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease". J. Clin. Oneal., 1992, 10 (2), 243.

[12] Kavanagh J. J., Copeland L. J., Gershenson D. M., Saul P. B., Edwards C. L.: "A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer". Gynecol. Oneal., 1986, 24 (1), 23.

[13] McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F.C., Ettinger D. S., Armstrong D. K. et al.: "Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms". Ann. Intern. Med., 1989, 111 (4), 273.

[14] Trimble E. L., Adams J. D., Vena D., Hawkins M. J., Friedman M. A., Fisherman J. S. et al.: "Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103". J. Clin. Oneal., 1993, 11 (12), 2405.

[15] Thigpen J. T., Blessing J. A., Ball H., Hummel S. J., Barrett R. J.: "Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study". J. Clin. Oneal., 1994, 12 (9), 1748.47 (3), 282.

[16] Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C. et al.: "Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer". J. Clin. Oneal., 1997, 15 (1), 187.

[17] Loffler T. M., Freund W., Lipke J., Hausamen T. U.: "Scheduleand dose-intensified paclitaxel as weekly I-hour infusion in pretreated solid tumors: results of a phase 1/11 trial". Semin. Oneal., 1996, 23 (6 Suppl 16), 32.

[18] Andersson H., Horvath G., Mellqvist L., Westberg R.: "Taxol given weekly in advanced previously treated ovarian carcinomas - A pilot study". Int. J. Gynecol. Cancer, 1997, 7, 262.

[19] Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S. et al.: "Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin". J. Clin. Oneal., 1991, 9 (3), 389.

[20] Miller A. B., Hoogstraten B., Staquet M., Winkler A.: "Reporting results of cancer treatroent". Cancer, 1981, 47, 207.

[21] Rustin G. J. S., Nelstrop A. R. E., McClean P., Brady M. F., McGuire M. F., Hoskins W. J. et al.: "Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125". J. Clin. Oneal., 1996, 14 (5), 1545.

[22] Rustin G. J. S., Nelstrop A. R. E., Crawford M., Lederman J., Lambert H. E., Coleman L. R. et al.: "Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response to serum CA-125". J. Clin. Oneal., 1997, 15 (1), 172.

[23] Kaplan E. L., Meier P.: "Nonparametric estimation from incomplete observations". J. Am. Stat. Assoc., 1958, 53, 457.

[24] World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No 48. Geneva: WHO 1979.

[25] Bookman M., Malmstrom H., Bolis G. et al.: "Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treatment after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel". J. Clin. Oncol., 1998, 16, 3345.

[26] Shapiro J. D., Millward M. J., Rischein D. et al.: "Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel". Gynecol. Oneal., 1996, 63, 89.

[27] Rose P. G., Blessing J. A., Mayer A. R., Homesley H. D.: "Prolonged oral etoposide as second line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study". J. Clin. Oncol., 1998, 16, 405.

[28] Gordon A. N., Granai C. 0., Rose P. G. et al.: "Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer". J. Clin. Oncol., 2000, 18, 3093.

[29] Einzig A. I., Wiemik P. H., Sasloff J., Runowicz C., Goldberg G. L.: "Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma". J. Clin. Oneal., 1992, 10, 1748.

[30] Kohn E. C., Sarosy G., Bicher A. et al.: "Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer". J. Natl. Cancer Inst., I 994, 86, 18.

[31] Eisenhauer E., ten Bokkel Huinink W., Swenerton K. et al.: "European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infosion". J. Clin. Oneal., 1994, 12, 2654.

[32] Liebmann J. E., Cook J. A., Lipshultz C., Teague D., F isher J., Mitchell J. B.: "Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines". Br. J. Cancer, 1993, 68, 1104.

[33] Kelland L. R., Abel G.: "Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines". Cancer Chemother. Pharmacol., 1992, 30, 444.

[34] Markman M., Rose P., Jones E. et al.: "Ninety-six hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens". J. Clin. Oneal., 1998, 16, 1849.

[35] Seidman A. D., Hudis C. A., Albanel J. et al.: "Dose-intense therapy with weekly I-hour paclitaxel infusions in the treatment of metastatic breast cancer". J. Clin. Oneal., 1998, 16, 3353.

[36] Belotti D., Vergani V., Drudis T. et al.:'"The microtubule-affecting drug paclitaxel has antiangiogentic activity". Clin. Cancer Res., 1996, 2, 1843.

[37] Abu-Rustum N. R., Aghajanian C., Barakat R., Fennelly D., Shapiro F., Spriggs D.: "Salvage weekly paclitaxel in recurrent ovarian cancer". Semin. Oneal., 1997, 24, 62.

[38] Bookman M. A.: "Extending the platinum-free interval m recurrent ovarian cancer: the role of Topotecan in second-line chemotherapy". The Oncologist, 1999, 4, 87.

[39] Judson P. L., Watson J.M., Gehrig P.A. et al.: "Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy". Cancer Res., 1999, 59, 2425.